Bausch + Lomb has received U.S. FDA approval for its enVista^® Envy^™ full range of vision intraocular lens, which provides continuous vision correction with enhanced dysphotopsia tolerance, a common issue with multifocal lenses.

The lens is designed for patients undergoing cataract surgery and offers both toric and non-toric options to address presbyopia and astigmatism. It is expected to enhance postoperative quality of life by improving both near and distance vision, and reducing the need for corrective eyewear. It provides enhanced accuracy with small steps in cylinder power for greater precision.

Most patients reported excellent visual performance in a multicenter, randomized, controlled clinical trial that evaluated 332 subjects: 92% achieved 20/20 vision at distance and 83% achieved 20/25 or better at intermediate distances without glasses. In the same trial, 86% of patients reported little to no dysphotopsia (glare, halos, starbursts), a press release from Bausch + Lomb reported. The lens has also been studied in Canada with similar results.

The enVista^® Envy^™ intraocular lens will be commercially available broadly in 2025, but will be available on a limited basis in the U.S. in the coming weeks.

Please refer to the press release for safety information and indications.